Research and Markets: Investigation Report on China Rituximab Market, 2009 ... Business Wire (press release) Rituximab (trade names ""MabThera"" by Roche, ""Rituxan"" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. |
